Pharmaceutical

CHMP recommends AstraZeneca’s Tagrisso for EU approval for NSCLC

EMA's CHMP has recommended AstraZeneca's Tagrisso for approval in the European Union to treat individuals with NSCLC.

Nov 19, 2024 - 06:00
CHMP recommends AstraZeneca’s Tagrisso for EU approval for NSCLC
EMA's CHMP has recommended AstraZeneca's Tagrisso for approval in the European Union to treat individuals with NSCLC.
Read the original article

Tags:

Previous Article

AHA 2024: Tirzepatide improves outcomes for major heart failure with HFpEF and o...

Next Article

AstraZeneca picks first Treg cell therapy from Quell Therapeutics partnership

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

GSK obtains approval in Japan for shingles vaccine

GSK obtains approval in Japan for shingles vaccine

Jun 27, 2023

Opinion: Your health insurance may not be as good your state requires — and it’s perfectly legal

Opinion: Your health insurance may not be as good your ...

Jun 10, 2023

Ketamine by NRX Pharmaceuticals for Bipolar Disorder (M...

Feb 20, 2024